Pharmaceutical giant Bristol-Myers Squibb (BMS) treats an array of maladies through its vast lineup of therapies. The company's blockbuster drugs include cancer treatment Opdivo, Eliquis for stroke prevention, and rhemuatoid arthritis treatment Orencia. Most of the firm's sales come from products in the areas of oncology, cardiovascular care, immunology, and virology. BMS has global research facilities and manufacturing plants, mainly in the US and Europe, and its products are marketed to health care providers in 100 countries. The US accounts for more than half of sales. The firm acquired Celgene, which makes blockbuster Revlimid for multiple myeloma, for $74 billion in 2019.
See detailed business credit reports on other businesses or your own.
See detailed profiles for insights and prospects on this company's top competitors.
Essential information for a successful call
- EMPLOYEES (This Site) 1,200
- EMPLOYEES (All Sites) 23,300
- ASSETS (MIL USD) 129,944
- SALES (MIL USD) 26,145
- TICKER SYMBOL BMY
- Incorporated 1887
- FISCAL YEAR END DEC
- SALES GROWTH % 15.89%
Get in Touch with 14,875 Contacts
Giovanni CaforioChief Executive Officer
GIOVANNI CAFORIOChairman of the Board and Chief Executive Officer
DAVID V ELKINSExecutive Vice President and Chief Financial Officer
SANDRA LEUNGExecutive Vice President and General Counsel